Gregory Piazza1, Benjamin Hohlfelder2, Michael R Jaff3, Kenneth Ouriel4, Tod C Engelhardt5, Keith M Sterling6, Noah J Jones7, John C Gurley8, Rohit Bhatheja9, Robert J Kennedy10, Nilesh Goswami11, Kannan Natarajan12, John Rundback13, Immad R Sadiq14, Stephen K Liu15, Narinder Bhalla16, M Laiq Raja17, Barry S Weinstock18, Jacob Cynamon19, Fakhir F Elmasri20, Mark J Garcia21, Mark Kumar22, Juan Ayerdi23, Peter Soukas24, William Kuo25, Ping-Yu Liu26, Samuel Z Goldhaber3. 1. Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: gpiazza@partners.org. 2. Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 3. Cardiovascular Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 4. Syntactx, New York, New York. 5. East Jefferson General Hospital, Metairie, Louisiana. 6. Cardiovascular and Interventional Associates, INOVA Alexandria Hospital, Alexandra, Virginia. 7. Mt. Carmel East Hospital, Columbus, Ohio. 8. Gill Heart Institute, University of Kentucky, Lexington, Kentucky. 9. Florida Heart Group, Florida Hospital, Orlando, Florida. 10. Holmes Regional Medical Center, Melbourne, Florida. 11. Prairie Heart Institute, St. John's Hospital, Springfield, Illinois. 12. St. Vincent Medical Group, Indianapolis, Indiana. 13. Holy Name Medical Center, Teaneck, New Jersey. 14. Vascular Medicine Division, Hartford Hospital, Hartford, Connecticut. 15. Lifelink Interventional Center, Memorial Medical Center, Modesto, California. 16. River Region Cardiology Associates, Baptist Medical Center, Montgomery, Alabama. 17. El Paso Cardiology Associates, PA, Providence Memorial Hospital and Sierra Medical Hospital, El Paso, Texas. 18. Leesburg Regional Medical Center, Leesburg, Florida. 19. Division of Vascular Intervention Radiology, Department of Radiology, Montefiore Medical Center, Bronx, New York. 20. Radiology and Imaging Specialists of Lakeland, Lakeland Regional Medical Center, Lakeland, Florida. 21. Christiana Care Center for Heart and Vascular Health, Newark, Delaware. 22. The Cardiovascular Care Group, Overlook Medical Center, Summit, New Jersey. 23. Macon Cardiovascular Institute, Medical Center of Georgia, Macon, Georgia. 24. Miriam Cardiology Inc., The Miriam Hospital, Providence, Rhode Island. 25. Stanford University, Stanford, California. 26. Fred Hutchinson Cancer Center, Seattle, Washington.
Abstract
OBJECTIVES: This study conducted a prospective, single-arm, multicenter trial to evaluate the safety and efficacy of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis, using the EkoSonic Endovascular System (EKOS, Bothell, Washington). BACKGROUND: Systemic fibrinolysis for acute pulmonary embolism (PE) reduces cardiovascular collapse but causes hemorrhagic stroke at a rate exceeding 2%. METHODS: Eligible patients had a proximal PE and a right ventricular (RV)-to-left ventricular (LV) diameter ratio ≥0.9 on chest computed tomography (CT). We included 150 patients with acute massive (n = 31) or submassive (n = 119) PE. We used 24 mg of tissue-plasminogen activator (t-PA) administered either as 1 mg/h for 24 h with a unilateral catheter or 1 mg/h/catheter for 12 h with bilateral catheters. The primary safety outcome was major bleeding within 72 h of procedure initiation. The primary efficacy outcome was the change in the chest CT-measured RV/LV diameter ratio within 48 h of procedure initiation. RESULTS: Mean RV/LV diameter ratio decreased from baseline to 48 h post-procedure (1.55 vs. 1.13; mean difference, -0.42; p < 0.0001). Mean pulmonary artery systolic pressure (51.4 mm Hg vs. 36.9 mm Hg; p < 0.0001) and modified Miller Index score (22.5 vs. 15.8; p < 0.0001) also decreased post-procedure. One GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries)-defined severe bleed (groin hematoma with transient hypotension) and 16 GUSTO-defined moderate bleeding events occurred in 15 patients (10%). No patient experienced intracranial hemorrhage. CONCLUSIONS: Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis decreased RV dilation, reduced pulmonary hypertension, decreased anatomic thrombus burden, and minimized intracranial hemorrhage in patients with acute massive and submassive PE. (A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE) [SEATTLE II]; NCT01513759).
OBJECTIVES: This study conducted a prospective, single-arm, multicenter trial to evaluate the safety and efficacy of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis, using the EkoSonic Endovascular System (EKOS, Bothell, Washington). BACKGROUND: Systemic fibrinolysis for acute pulmonary embolism (PE) reduces cardiovascular collapse but causes hemorrhagic stroke at a rate exceeding 2%. METHODS: Eligible patients had a proximal PE and a right ventricular (RV)-to-left ventricular (LV) diameter ratio ≥0.9 on chest computed tomography (CT). We included 150 patients with acute massive (n = 31) or submassive (n = 119) PE. We used 24 mg of tissue-plasminogen activator (t-PA) administered either as 1 mg/h for 24 h with a unilateral catheter or 1 mg/h/catheter for 12 h with bilateral catheters. The primary safety outcome was major bleeding within 72 h of procedure initiation. The primary efficacy outcome was the change in the chest CT-measured RV/LV diameter ratio within 48 h of procedure initiation. RESULTS: Mean RV/LV diameter ratio decreased from baseline to 48 h post-procedure (1.55 vs. 1.13; mean difference, -0.42; p < 0.0001). Mean pulmonary artery systolic pressure (51.4 mm Hg vs. 36.9 mm Hg; p < 0.0001) and modified Miller Index score (22.5 vs. 15.8; p < 0.0001) also decreased post-procedure. One GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries)-defined severe bleed (groin hematoma with transient hypotension) and 16 GUSTO-defined moderate bleeding events occurred in 15 patients (10%). No patient experienced intracranial hemorrhage. CONCLUSIONS: Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis decreased RV dilation, reduced pulmonary hypertension, decreased anatomic thrombus burden, and minimized intracranial hemorrhage in patients with acute massive and submassive PE. (A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE) [SEATTLE II]; NCT01513759).
Authors: Matthew A Muller; Aris Xie; Yue Qi; Yan Zhao; Koya Ozawa; Misty Noble-Vranish; Jonathan R Lindner Journal: Ultrasound Med Biol Date: 2020-06-08 Impact factor: 2.998
Authors: Nathan L Liang; Efthymios D Avgerinos; Luke K Marone; Michael J Singh; Michel S Makaroun; Rabih A Chaer Journal: Vasc Endovascular Surg Date: 2016-08 Impact factor: 1.089
Authors: Nathan L Liang; Efthymios D Avgerinos; Michael J Singh; Michel S Makaroun; Rabih A Chaer Journal: J Vasc Surg Venous Lymphat Disord Date: 2017-01-16